Aphios Corporation Secures Patent Allowance for Novel Bryoid Composition Targeting Alzheimer’s, Multiple Sclerosis, HIV and Cancer

Aphios Corporation Receives Patent Allowance for Innovative Bryoid Composition Platform Aimed at Alzheimer’s, Multiple Sclerosis, HIV Reservoirs, and Oncology Applications Aphios Corporation has announced that the United States Patent and…

Read MoreAphios Corporation Secures Patent Allowance for Novel Bryoid Composition Targeting Alzheimer’s, Multiple Sclerosis, HIV and Cancer

Inocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer

Inocras Presents Real-World Evidence Supporting Whole-Genome HRD Profiling in Ovarian Cancer Treatment Inocras, a bioinformatics-driven precision oncology company specializing in whole-genome sequencing and advanced genomic analytics, has announced that new…

Read MoreInocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer

Agios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience

Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood…

Read MoreAgios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience